Researchers have discovered that a nonsteroid anti-inflammatory drug used for treating colds suppresses the spread of bladder cancers and reduces their chemoresistance in mice, raising hopes of a future cure for advanced bladder cancers

The results are published in Scientific Reports.

Bladder cancer is the seventh most common cancer in males worldwide.

Every year, about 20,000 people in Japan are diagnosed with bladder cancer, of whom around 8,000--mostly men--succumb to the disease.

Bladder cancers can be grouped into two types: non-muscle-invasive cancers, which have a five-year survival rate of 90 percent, and muscle-invasive cancers, which have poor prognoses.

The latter are normally treated with such anticancer drugs as cisplatin, but tend to become chemoresistant and, thus, spread to organs such as the lungs and liver, as well as bone.

In the latest research, human bladder cancer cells labelled with luciferase were inoculated into mice, creating a xenograft bladder cancer model.

The primary bladder xenograft gradually grew and, after 45 days, metastatic tumours were detected in the lungs, liver and bone.

By using a microarray analysis including more than 20,000 genes for the metastatic tumours, the team discovered a three- to 25-fold increase of the metabolic enzyme aldo-keto reductase 1C1 (AKR1C1).

They also found high levels of AKR1C1 in metastatic tumours removed from 25 cancer patients, proving that the phenomena discovered in the mice also occur in the human body.

Along with anticancer drugs, an inflammatory substance produced around the tumour, such as interleukin-1β, increased the enzyme levels.

The researchers also identified for the first time that AKR1C1 enhances tumour-promoting activities and proved that the enzyme blocks the effectiveness of cisplatin and other anticancer drugs.

The researchers finally discovered that inoculating flufenamic acid, an inhibitory factor for AKR1C1, into cancerous bladder cells suppressed the cells' invasive activities and restored the effectiveness of anticancer drugs.

Flufenamic acid is also known as a nonsteroid anti-inflammatory drug used for treating common colds.

The team's discovery is expected to spur clinical tests aimed at improving prognoses for bladder cancer patients.

In the latest cancer treatments, expensive molecular-targeted drugs are used, putting a large strain on both the medical economy and the state coffers. "This latest research could pave the way for medical institutions to use flufenamic acid--a much cheaper cold drug--which has unexpectedly been proven to be effective at fighting cancers," says Dr. Shinya Tanaka of the research group.

The research was conducted in collaboration with Dr. Nobuo Shinohara of the Department of Renal and Genitourinary Surgery at Hokkaido University; the article's lead author was postgraduate student Ryuji Matsumoto.

Source: Scientific Reports